BioSenic appoints Yves Sagot as Independent Director

BioSenic appoints Yves Sagot as Independent Director

Mont-Saint-Guibert, Belgium, January 27, 2023 – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune / inflammatory diseases and cell repair, today announces the appointment of Yves Sagot as a Member of the Board and Independent Director. 

Yves Sagot has been appointed to the BioSenic board for his experience and achievements for Relief Therapeutics SA and a number of specific aspects that mirror recent BioSenic developments. 

Yves co-founded Relief Therapeutics in 2013 to develop a clinical asset acquired from Merck Serono. In 2016, Relief Therapeutics went public on the Swiss stock exchange (SIX) after a reverse merger with THERAMetrics. Whilst maintaining his activities as Chief Scientific Officer at Relief Therapeutics, Yves created MBS Sagot Consulting in 2018 to provide to the life science market senior expertise covering research and early clinical development. Subsequently, after leaving Relief Therapeutics, he is a private investor in biotechnology via MBS Invest and Consult Sàrl. He is also one of the ambassadors of the Léon Bérard Cancer Center, an internationally recognized research center in Lyon, France. He has authored 25 papers that have been published in international peer-reviewed journals, holds three granted patents and received the Serono CEO Award in 2001 and the Merck Serono Reward and Recognition Award in 2008.

Yves Sagot replaces Terry Sadler as an Independent Director and Member of the Board at BioSenic.

“BioSenic has now completed the acquisition of the majority participation in Medsenic and is now focused on ongoing clinical development on both platforms. As a result, BioSenic is now building further expertise in its senior teams, with recent appointments of a Chief Medical Officer that is responsible for the development of both of BioSenic’s cell therapy and autoimmune disease platforms, and a Chief Scientific Officer to manage BioSenic’s scientific research and development,” said Prof. François Rieger, President and CEO of BioSenic. “We are additionally focusing on ensuring our board of directors has the optimal composition of expertise. Yves Sadler has highly relevant and complimentary professional experience, specifically as a co-founder of a European biotech that also went public following a merger. His ongoing advice and contributions will be vital as BioSenic continues to demonstrate value to investors through development of our pipeline of therapies developed through our cell therapy and autoimmune disease platforms. I would also like to thank Terry Sadler for his contribution as an Independent Director through the acquisition process.”

“The creation of BioSenic has resulted in an intriguing biotech company with multiple targets and platforms. These number of platforms spreads risk, and also will result in increased innovation as the differing expertise of scientific teams share strategies and ideas. As a result, this should be highly attractive for investors,” said Yves Sagot, Independent Director and Member of the Board at BioSenic. “This is a major reason why I have accepted to join the BioSenic board and offer my additional expertise as an Independent Director. The combination now of the experience of the board will provide a significant contribution to the senior team as they develop therapies for patients suffering from a range of high unmet medical needs.”

Yves received a Certificate of Advanced Studies in Management of Medtech, Biotech & Pharma Ventures from the Management of Technology EPFL in Lausanne, Switzerland., holds a Ph.D in Neurobiology and a Masters in Pharmacology and Fundamental Toxicology from the Université Paul Sabatier (UPS), Toulouse, France.